Market Overview

Ligand Pharmaceuticals Sees Q4 EPS $0.31-$0.32 vs $0.22-$0.24; Q4 Revenue $14.0M-$14.5M vs $11.0M-$12.0M

Share:

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) is revising
upward its previous revenue and net income guidance for the fourth
quarter and full year 2013 as a result of higher-than-expected sales of
Captisol® material. Ligand now expects total revenues for the
fourth quarter of 2013 to be between $14.0 million and $14.5 million,
compared with previous guidance of between $11.0 million and $12.0
million. Non-GAAP earnings from continuing operations per diluted share
for the fourth quarter of 2013 is expected to be between $0.31 and
$0.32, compared with previous guidance of between $0.22 and $0.24.

For the full year 2013, Ligand expects total revenues to be between
$48.0 million and $48.5 million, compared with previous guidance of

See full press release

Posted-In: Earnings News Guidance Contracts Asset Sales Management Global

 

Related Articles (LGND)

View Comments and Join the Discussion!